SOLUBLE RECEPTORS FOR TUMOR NECROSIS FACTOR AND LIPID METABOLISM AS POTENTIAL PROGNOSTIC FACTORS IN PATIENTS WITH PROSTATE CANCER
Vol. 59 No. 1 (2013), Articles
Vol. 59 No. 1 (2013)

SOLUBLE RECEPTORS FOR TUMOR NECROSIS FACTOR AND LIPID METABOLISM AS POTENTIAL PROGNOSTIC FACTORS IN PATIENTS WITH PROSTATE CANCER

Articles
https://doi.org/10.37469/0507-3758-2013-59-1-72-77
Published 15.12.2013
Russian Cardiology Research and Production Complex
Russian Cardiology Research and Production Complex
Russian Cardiology Research and Production Complex
Russian Cardiology Research and Production Complex
Russian Cardiology Research and Production Complex
Russian Research Center of Radiology and Surgical Technologies
Russian Research Center of Radiology and Surgical Technologies
Russian Research Center of Radiology and Surgical Technologies
Russian Cardiology Research and Production Complex
Russian Cardiology Research and Production Complex
##article.numberofdownloads## 28
##article.numberofviews## 59
PDF (Русский)

Keywords

рак предстательной железы
растворимые рецепторы к фактору некроза опухоли (ФНО)
липидный обмен
липопротеид(а)

How to Cite

, , , , , , , , , & . (2013). SOLUBLE RECEPTORS FOR TUMOR NECROSIS FACTOR AND LIPID METABOLISM AS POTENTIAL PROGNOSTIC FACTORS IN PATIENTS WITH PROSTATE CANCER. Voprosy Onkologii, 59(1), 72–77. https://doi.org/10.37469/0507-3758-2013-59-1-72-77
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

There was investigated the relationship of lipid metabolism, humoral immunity, high sensitivity C-reactive protein and soluble receptors for TNF-а with the presence, severity and prognosis of the disease in 85 patients with morphologically verified diagnosis of prostate cancer. Connection with the dynamics of change in PSA as a major predictor of the disease was observed for concentration sRI and sRII to TNF, PSA baseline, total cholesterol and LDL-cholesterol. During follow-up the relative risk of poor prognosis increased by 3 times, and death—in 8.7 times with increasing concentrations of soluble receptors for TNF. The concentration of soluble receptors for TNF may serve as an additional predictor of the presence and clinical course of disease in patients with prostate cancer.
https://doi.org/10.37469/0507-3758-2013-59-1-72-77
##article.numberofdownloads## 28
##article.numberofviews## 59
PDF (Русский)

References

Афанасьева О.П., Адамова И.Ю., Беневоленская Г.Ф. и др. Иммуноферментный метод определения липопротеида (а) // Бюлл. эксперим. биол. мед. — 1995 — № 10. — С. 398-401.

Aderka D., Engelmann I., Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients// Cancer Res. — 1991. — Vol. 51. — P. 5602-5607.

Aderka D., Engelmann H., Shemer-Avni Y. et al. Variation in serum levels of the soluble TNF receptors among healthy individuals // Lymphok Cytok Res. — 1992. — Vol. 11(3). — P. 157-159.

DAmico A.V., Moul J., Carroll P.R. at al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy // J Urol. — 2004. — Vol. 172 (5 Pt 2). — P. S42-S46.

Gadducci A., Ferdeghini M., Fanucchi A. et al. Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFR) in endometrial cancer // Anticancer Res. — 1996. — 16 (5B). — P. 3125-3128.

Jablonska E., Kiluk M., Piotrowski L. et al. Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients // European Cytokine Network. - 1998. — Vol. 9 (2). — P. 155- 159.

Kirby R.S. Pre-treatment staging of prostate cancer: recent advances and future prospects // Prostate Cancer Prostatic Dis. — 1997. — Vol. l (l). — P. 2-10.

Magura L., Blanchard R., Hope B. et al. Hypercholesterolemia and prostate cancer: a hospital-based case-control study // Cancer Causes Control. - 2008. — Vol. 19 (10). — P. 1259-1266.

Mannel D.N., Moore R.N., Mergenhagen S.E. Macrophages as a source of tumoricidal activity (tumor-necrotizing factor) // Infect Immun. — 1980. — Vol. 30 (2). — P. 523-530.

Platz E.A., Till C., Goodman P.J., Parnes H.L. et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial // Cancer Epidemiol Biomarkers Prev. - 2009. — Vol. 18 (11). — P. 2807-2813.

Puztai L., Clouse L.M., Cooper K., Starkey PM. et al. Expression of tumor necrosis factor a and its receptors in carcinoma of the breast // Br J Cancer. — 1994. — Vol. 70. — P. 289-292.

Stamey T.A., Kabalin J.N., McNeal J.E. et al. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients // J Urol. — 1989. — Vol. 141. — P. 1076-1083.

Studer U.E., Collette L., Whelan P. at al. EORTC Genitourinary Group. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) // Eur Urol. -2008. — Vol. 53 (5). — P. 941-949.

Wuermli L., Joerger M., Henz S. et al. Hypertriglyceridemia as a possible risk factor for prostate cancer // Prostate Cancer Prostatic Dis. — 2005. — Vol. 8 (4). — P. 316-320.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...